| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
FORT LAUDERDALE, Fla.—A major full-service, global contract research organization (CRO) has expanded its existing partnership with OmniComm Systems Inc., a leading global provider of clinical data management technology. Under the terms of a new $7.8-million multiyear agreement, the CRO will utilize OmniComm’s TrialOne system to ensure regulatory compliance and bring greater operational efficiency, speed and quality to the clinical research process within its clinics.
 
The CRO in question will use TrialOne to implement a number of automated clinical trial processes across multiple clinics, including the recruitment and screening of subject participants, study design and the collection, analysis and reporting of data.
 
“We’re excited to continue building our partnership with this leading CRO,” said Dr. Kuno van der Post, chief commercial officer at OmniComm. “We are very proud to have earned their trust for increased business and commitment. It is a pleasure to work with a company that shares our passion for problem solving for clients and seeks robust, scalable and innovative solutions to help meet expectations.”
 
TrialOne is a browser-based bedside data collection technology specifically designed to automate the workflows and processes within early-phase research clinics.

Related Topics

Published In

Volume 14 - Issue 10 | October 2018

October 2018

October 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue